All In Biotech

Drug Trial Radar · NCT01728064

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Last checked: Nov 20, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 31, 2012

Primary completion

Oct 31, 2015

Study completion Feb 29, 2016

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.

Conditions

  • Friedreich's Ataxia

Interventions

  • PlaceboDrug

    Placebo capsules

  • EPI-743 400 mgDrug

  • EPI-743 200 mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Function

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • University of South Florida

    Tampa, Florida

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.